SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    J. Bolinder, Ö. Ljunggren, L. Johansson, J. Wilding, A. M. Langkilde, C. D. Sjöström, J. Sugg, S. Parikh, Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin, Diabetes, Obesity and Metabolism, 2014, 16, 2
  2. 2
    M. E. Rotz, V. S. Ganetsky, S. Sen, T. F. Thomas, Implications of incretin-based therapies on cardiovascular disease, International Journal of Clinical Practice, 2014, 68, 12
  3. 3
    Anthony H Barnett, Linagliptin for the treatment of type 2 diabetes mellitus: a drug safety evaluation, Expert Opinion on Drug Safety, 2014, 1

    CrossRef

  4. 4
    Kate McKeage, Linagliptin: An Update of Its Use in Patients with Type 2 Diabetes Mellitus, Drugs, 2014, 74, 16, 1927

    CrossRef

  5. 5
    Robert R. Henry, Antihyperglycemic Drug Therapy in Patients with Diabetes and CKD: A Closer Look at Incretin-Based Therapies, Endocrine Practice, 2013, 19, s1, 19

    CrossRef

  6. 6
    Manuel González-Ortiz, María J. Sánchez-Peña, Luis J. González-Ortiz, José A. Robles-Cervantes, Yessica E. García-Ortega, Esteban A. Gómez-Gaitán, Karina G. Pérez-Rubio, Esperanza Martínez-Abundis, Effect of Vildagliptin on Glucose and Insulin Concentrations During a 24-Hour Period in Type 2 Diabetes Patients with Different Ranges of Baseline Hemoglobin A1c Levels, Diabetes Technology & Therapeutics, 2013, 15, 7, 564

    CrossRef

  7. 7
    André J Scheen, Efficacy and safety of Jentadueto® (linagliptin plus metformin), Expert Opinion on Drug Safety, 2013, 12, 2, 275

    CrossRef

  8. 8
    Jaime A. Davidson, Incretin-Based Therapies: Focus on Effects Beyond Glycemic Control Alone, Diabetes Therapy, 2013, 4, 2, 221

    CrossRef

  9. 9
    B. Gallwitz, J. Rosenstock, A. Emser, M. Eynatten, H.-J. Woerle, Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA1c < 7% with no hypoglycaemia and no weight gain over 2 years, International Journal of Clinical Practice, 2013, 67, 4
  10. 10
    André J Scheen, Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation, Expert Opinion on Drug Metabolism & Toxicology, 2013, 9, 3, 363

    CrossRef

  11. 11
    Erika Paniago Guedes, Alexandre Hohl, Thais Gomes de Melo, Felipe Lauand, Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment, Diabetology & Metabolic Syndrome, 2013, 5, 1, 25

    CrossRef

  12. You have free access to this content12
    George Grunberger, Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013 (新型2型糖尿病治疗药物:第2部分. 2013年临床上针对肠促胰岛素缺陷的治疗药物), Journal of Diabetes, 2013, 5, 3
  13. 13
    Jaime A. Davidson, The Placement of DPP-4 Inhibitors in Clinical Practice Recommendations for the Treatment of Type 2 Diabetes, Endocrine Practice, 2013, 19, 6, 1050

    CrossRef

  14. 14
    Emma D. Deeks, Linagliptin, Drugs, 2012, 72, 13, 1793

    CrossRef

  15. 15
    Long-term linagliptin effective treatment for Type 2 diabetes, Springer Healthcare News, 2012, 1, 1

    CrossRef

  16. 16
    Rosemarie Lajara, Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes, Expert Opinion on Pharmacotherapy, 2012, 13, 18, 2663

    CrossRef